Literature DB >> 17119054

Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa.

Oleg K Glebov1, Luz M Rodriguez, Peter Soballe, John DeNobile, Janet Cliatt, Kenneth Nakahara, Ilan R Kirsch.   

Abstract

Aberrant crypt foci (ACF) are considered the earliest identifiable preneoplastic colonic lesions; thus, a greater understanding of the nature of genetic changes underlying the transformation of normal colonic mucosa (NM) into ACF may provide insight into the mechanisms of carcinogenesis. ACF were identified by indigo carmine spraying onto colonic mucosa during colonoscopy and isolated as standard pinch biopsies of the mucosal areas containing the ACF. RNAs isolated from ACF and matched NM biopsies from the ascending and descending colons of 13 patients were analyzed on arrays containing 9128 cDNAs. Thirty-four differentially expressed (P < 0.001) genes were found in a paired comparison of the ACF and NM samples, and 25 of 26 matched pairs of ACF and NM could be correctly classified in leave-one-out cross-validation. Differential expression for seven of eight genes was confirmed by real-time reverse transcription-PCR. Furthermore, ACF and NM samples, including six pairs of ACF and NM samples that had not previously been analyzed by array hybridization, can be correctly classified on the basis of the overexpression in ACF of three selected genes (REG4, SRPN-B5, and TRIM29) evaluated by real-time reverse transcription-PCR. In a separate analysis of 13 biopsy pairs from either ascending or descending colon, ACF and NM samples could also be correctly classified by the gene expression patterns. Analysis of gene expression differences in ACF from the ascending and descending colon versus NM samples indicates that ACF from these distinct colonic locations are converging toward similar gene expression profiles and losing differences in gene expression characteristic of NM from the ascending versus descending colon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119054     DOI: 10.1158/1055-9965.EPI-05-0694

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  21 in total

1.  TRIM29 suppresses TWIST1 and invasive breast cancer behavior.

Authors:  Lingbao Ai; Wan-Ju Kim; Merve Alpay; Ming Tang; Carolina E Pardo; Shigetsugu Hatakeyama; W Stratford May; Michael P Kladde; Coy D Heldermon; Erin M Siegel; Kevin D Brown
Journal:  Cancer Res       Date:  2014-06-20       Impact factor: 12.701

2.  The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions.

Authors:  Zhigang Yuan; Alejandro Villagra; Lirong Peng; Domenico Coppola; Michele Glozak; Eduardo M Sotomayor; Jiandong Chen; William S Lane; Edward Seto
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

Review 3.  Inflammatory pathways in the early steps of colorectal cancer development.

Authors:  Francesco Mariani; Paola Sena; Luca Roncucci
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.

Authors:  Muzaffer Dükel; W Scott Streitfeld; Tsz Ching Chloe Tang; Lindsey R F Backman; Lingbao Ai; W Stratford May; Kevin D Brown
Journal:  J Biol Chem       Date:  2016-08-17       Impact factor: 5.157

5.  TRIM proteins and cancer.

Authors:  Shigetsugu Hatakeyama
Journal:  Nat Rev Cancer       Date:  2011-10-07       Impact factor: 60.716

Review 6.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

7.  Ataxia-telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways.

Authors:  Zhong-Ping Tang; Quan-Zhe Cui; Qian-Ze Dong; Ke Xu; En-Hua Wang
Journal:  Tumour Biol       Date:  2013-05-17

8.  The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.

Authors:  Jieru Egeria Lin; Peng Li; Adam Eugene Snook; Stephanie Schulz; Abhijit Dasgupta; Terry Marie Hyslop; Ahmara Vivian Gibbons; Glen Marszlowicz; Giovanni Mario Pitari; Scott Arthur Waldman
Journal:  Gastroenterology       Date:  2009-09-06       Impact factor: 22.682

9.  GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity.

Authors:  Jieru Egeria Lin; Adam Eugene Snook; Peng Li; Brian Arthur Stoecker; Gilbert Won Kim; Michael Sullivan Magee; Alex Vladimir Mejia Garcia; Michael Anthony Valentino; Terry Hyslop; Stephanie Schulz; Scott Arthur Waldman
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

10.  Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway.

Authors:  Zhong-Ping Tang; Qian-Ze Dong; Quan-Zhe Cui; Paulie Papavassiliou; En-Di Wang; En-Hua Wang
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.